Skip to main content

Performance of cardiac output measurement derived from arterial pressure waveform analysis in patients undergoing triple-H-therapy of cerebral vasospasms after subarachnoidal hemorrhage

Introduction

The validity of an arterial waveform-based device for measuring cardiac output (CO) without the need for invasive calibration (FloTrac/Vigileo) in patients needing large doses of vasoactive medication has not yet been thoroughly studied. We performed the present study to assess the validity of both the second-generation and the third-generation software compared with transpulmonary thermodilution CO measurement using the PiCCO technology in patients undergoing triple-H-therapy (hypertonia, hypervolemia, hemodilution) of cerebral vasospasms after subarachnoidal hemorrhage.

Methods

Twenty-three patients (18 females and five males) were included in this study. All of them were suffering from a subarachnoidal hemorrhage (Hunt&Hess grade I to V) due to rupture of a cerebral aneurysm. Triple-H-therapy was initiated for the treatment of cerebral vasospasm. Simultaneous CO measurements by bolus thermodilution and the FloTrac/Vigileo device were obtained at baseline as well as 2 hours, 6 hours, 12 hours, 24 hours, 48 hours and 72 hours after inclusion. A percentage error of 30% or less was established as the criterion for method interchangeability.

Results

Patients received vasoactive support with 0.53 ± 0.46 μg/kg/minute norepinephrine, resulting in a mean arterial pressure of 104 ± 13.6 mmHg and a systemic vascular resistance index of 1,741.17 ± 432.50 dyn·s/cm5/m2. One hundred and fifty-one CO-data pairs were analyzed. Transpulmonary thermodilution CO ranged from 5.18 to 14.28 l/minute (mean 8.61 ± 1.93 l/minute) and FloTrac/Vigileo CO ranged from 4.1 to 13.7 l/minute (mean 7.62 ± 1.79 l/minute). Bias and precision (1.96SD of the bias) were 0.99 l/minute and 2.46 l/minute, resulting in an overall percentage error of 28.55%. Subgroup analysis revealed a percentage error of 29.53% for 67 data pairs measured using the second-generation FloTrac software and 26.44% for 84 data pairs analyzed by the third-generation software.

Conclusions

In patients undergoing triple-H-therapy and needing extensive vasoactive support, CO values obtained by arterial waveform analysis showed good agreement with intermittent transpulmonary thermodilution CO measurements, which was improved by the introduction of a new software generation.

References

  1. 1.

    Mayer J, Boldt J, Wolf MW, Lang J, Suttner S: Cardiac output derived from arterial pressure waveform analysis in patients undergoing cardiac surgery: validity of a second generation device. Anesth Analg. 2008, 106: 867-872. 10.1213/ane.0b013e318161964d. table

    PubMed  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to SM Metzelder.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Metzelder, S., Kopp, R., Fries, M. et al. Performance of cardiac output measurement derived from arterial pressure waveform analysis in patients undergoing triple-H-therapy of cerebral vasospasms after subarachnoidal hemorrhage. Crit Care 14, P103 (2010). https://doi.org/10.1186/cc8335

Download citation

Keywords

  • Cardiac Output
  • Subarachnoidal Hemorrhage
  • Percentage Error
  • Cerebral Vasospasm
  • Waveform Analysis